In the 1960s, a number of integrative Chinese and Western medicine （ICWM） surgeons （such as Prof. WU Xian-zhong） first started the application of traditional Chinese medicine （TCM） in acute abdominal surgery, an...In the 1960s, a number of integrative Chinese and Western medicine （ICWM） surgeons （such as Prof. WU Xian-zhong） first started the application of traditional Chinese medicine （TCM） in acute abdominal surgery, and thus they became the pioneers of perioperative therapy with ICWM. Since then, they haveaccumulated abundant experience in this field. At the 1st National Conference of Perioperative Therapy with ICWM in November 1994, the academician WU Xian-zhong, et al believed that perioperative therapy with ICWM hold promise for the future.展开更多
Incidence rates for esophagogastric junction cancer are rising rapidly worldwide possibly due to the economic development and demographic changes.Therefore,increased attention has been paid to the prevention,diagnosis...Incidence rates for esophagogastric junction cancer are rising rapidly worldwide possibly due to the economic development and demographic changes.Therefore,increased attention has been paid to the prevention,diagnosis,and the treatment of esophagogastric junction cancer.Although there are discrepancies in the treatment strategy between Asian and Western countries,surgery remains the mainstay of treatment for esophagogastric junction cancer.Recent developments of perioperative multidisciplinary treatment may lead to better therapeutic effect,higher complete resection rate,and better control of the residual diseases,thus result in prolonged prognosis.In this review,we will focus on the treatment of locally advanced resectable esophagogastric junction cancer,and discuss the current status and future perspectives of the perioperative treatment including chemotherapy,radiation therapy,and immunotherapy,as well as the surgical strategy.Better understanding of the latest treatment strategy and future overlook may enable to standardize and individualize the treatment for esophagogastric junction cancer,thus leading to better prognosis for those patients.展开更多
Background The probability and risk of operations increase in patients with type 2 diabetes mellitus. For diabetic patients, blood glucose control is a key factor to improving the prognosis of surgery. During perioper...Background The probability and risk of operations increase in patients with type 2 diabetes mellitus. For diabetic patients, blood glucose control is a key factor to improving the prognosis of surgery. During perioperative period, insulin therapy is usually advised to be used for surgical patients with type 2 diabetes. However, the insulin regimen which one is better remains controversial. In this study, we estimated the efficacy, safety and advantage of different insulin therapy strategy during perioperative period.展开更多
文摘In the 1960s, a number of integrative Chinese and Western medicine （ICWM） surgeons （such as Prof. WU Xian-zhong） first started the application of traditional Chinese medicine （TCM） in acute abdominal surgery, and thus they became the pioneers of perioperative therapy with ICWM. Since then, they haveaccumulated abundant experience in this field. At the 1st National Conference of Perioperative Therapy with ICWM in November 1994, the academician WU Xian-zhong, et al believed that perioperative therapy with ICWM hold promise for the future.
文摘Incidence rates for esophagogastric junction cancer are rising rapidly worldwide possibly due to the economic development and demographic changes.Therefore,increased attention has been paid to the prevention,diagnosis,and the treatment of esophagogastric junction cancer.Although there are discrepancies in the treatment strategy between Asian and Western countries,surgery remains the mainstay of treatment for esophagogastric junction cancer.Recent developments of perioperative multidisciplinary treatment may lead to better therapeutic effect,higher complete resection rate,and better control of the residual diseases,thus result in prolonged prognosis.In this review,we will focus on the treatment of locally advanced resectable esophagogastric junction cancer,and discuss the current status and future perspectives of the perioperative treatment including chemotherapy,radiation therapy,and immunotherapy,as well as the surgical strategy.Better understanding of the latest treatment strategy and future overlook may enable to standardize and individualize the treatment for esophagogastric junction cancer,thus leading to better prognosis for those patients.
文摘Background The probability and risk of operations increase in patients with type 2 diabetes mellitus. For diabetic patients, blood glucose control is a key factor to improving the prognosis of surgery. During perioperative period, insulin therapy is usually advised to be used for surgical patients with type 2 diabetes. However, the insulin regimen which one is better remains controversial. In this study, we estimated the efficacy, safety and advantage of different insulin therapy strategy during perioperative period.
